Pharmaceutical policies in post-communist Albania: Progress and challenges toward European Union membership by Roshi, Dajana et al.
 
 
Roshi D, Tresa E, Lafranconi A, Burazeri G, Czabanowska K, Brand H.  Pharmaceutical policies in 
post-communist Albania: Progress and challenges toward European Union membership (Review 
article). SEEJPH 2021, posted: 19 July 2021. DOI: 10.11576/seejph-4604 
 
 
P a g e 1 | 13 
 
      REVIEW ARTICLE 
 
Pharmaceutical policies in post-communist Albania: Progress and challenges 
toward European Union membership  
 
Dajana Roshi1,2*, Eni Tresa1,3*, Alessandra Lafranconi1, Genc Burazeri1,3,  





1 Department of International Health, School CAPHRI (Care and Public Health Research Institute), 
Maastricht University, Maastricht, The Netherlands; 
 
2 National Agency for Drugs and Medical Devices, Tirana, Albania; 
 
3 Department of Public Health, Faculty of Medicine, University of Medicine, Tirana, Albania; 
 
4 Institute of Public Health, Faculty of Health Sciences, Jagiellonian University, Krakow, Poland. 
 
 




Corresponding author: Dajana Roshi, MSc;  
Address: National Agency for Drugs and Medical Devices, Dibra Street No. 359/1, Tirana, Alba-
nia;  












Roshi D, Tresa E, Lafranconi A, Burazeri G, Czabanowska K, Brand H.  Pharmaceutical policies in 
post-communist Albania: Progress and challenges toward European Union membership (Review 
article). SEEJPH 2021, posted: 19 July 2021. DOI: 10.11576/seejph-4604 
 
 





Aim: Shifting from a communist regime to a democratic system has affected health system fun-
damentally in most of the Western Balkan countries including Albania. Albania became a Euro-
pean Union (EU) candidate country in 2014. Since then, one of the main concerns has been to 
approximate the legislation with the EU framework. The aim of this paper is to review the evolve-
ment of pharmaceutical legislation in Albania and challenges toward achieving full approximation 
to the EU’s respective legislation. 
 
Methods: We used qualitative techniques, especially means of conventional content analysis and 
two sources to collection data. First, we consulted the Albania’s National Publications Office 
webpage and analysed all available legislation regarding “pharmacy”, “medicine” and “pharma-
ceutical products” from 1994 to 2021. Then, we analysed the National Integration Plans that have 
been published by the Government of Albania from 2014 to 2021. 
 
Results: The decrease of the price margin system goes in parallel with the increase of the pharma-
ceutical expenditure, including out-of-pocket expenditure on medicines and lack of adequate and 
sensitive reimbursement policies. The main pillars of the pharmaceutical sector in Albania are 
well-covered legally but not fully in concordance with the EU framework. 
 
Conclusion: There is a need to foster laws implementation that regulate the opening of pharma-
cies; a detailed regulation on pharmacovigilance; and a regulation on medicinal products for pae-
diatric use. Also, the existing legal framework should be aligned with the European one. Medicine 
pricing methods should go in the same line with the decrease of out-of-pocket expenditure. 
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The Western Balkan countries (WB) – Alba-
nia, Bosnia and Herzegovina, Republic of 
North Macedonia, Kosovo, Montenegro and 
Serbia – are facing a formidable array of chal-
lenges such as demographic, socio-economic 
and legislative (1). Beside the complex past, 
WB aspirate to join the European Union (EU) 
(2). Albania is a EU candidate country since 
June 2014 and, from March 2020, the EU 
opened the accession negotiations with Alba-
nia (3). The process of European Integration 
is followed by “construction, diffusion and 
implementation of formal and informal rules, 
procedures, policy paradigms, styles, ’ways 
of doing things,’ and shared beliefs and 
norms which are first defined and consoli-
dated in the EU policy process and then in-
corporated in the logic of domestic discourse, 
identities, political structures and public pol-
icy”, known as Europeanization process (4). 
The Albanian health system is mainly public, 
and the state provides the majority of services 
regarding promotion, prevention, diagnosis, 
and treatment of diseases (1). The private sec-
tor covers mostly the pharmaceutical and 
dental services, and some specialized diag-
nostic services (5). Never the less, the Euro-
peanization process in expected to influence 
health sector and contribute to protection of 
health, safety and economic interests of con-
sumers (6). In this regard, the government has 
started to align the pharmaceutical legislation 
and practices with the EU respective direc-
tives including measures to simplify the med-
icine registration, licensing of professionals 
and pharmacies, price controls and reim-
bursement of drugs and implication of ethical 
standards (7). The process of Europeaniza-
tion of medicines regulations “involves har-
monization and mutual recognition of regu-
latory decision making as well as the transfer 
of some authority from Member States to su-
pranational EU regulatory agencies” (8). 
However, there are differences in the way the 
countries approach new pharmaceutical leg-
islation including how various stakeholders 
are involved in policy making and how easy 
it is for the country to implement the new leg-
islative changes (9). 
The national European integration plans 
(NIP) have been regularly published and up-
dated since 2014 aiming at description of 
achievements and setting new objectives 
(10). In this regard, the Pharmaceutical Poli-
cies have been changing, as it is shown in the 
NIP and the Official Publications Centre 
(from 1994 to 2014) (10,11).  These changes 
are reflected in the Law on Medicines and 
Pharmaceutical Services, Clinical Trials, 
Medicine Pricing, Reimbursement Policies, 
the list of Over the Counter Medicines/ Med-
icines given without prescription (OTC), and 
the Pharmaceutical Education, laws that  reg-
ulate the most important parts of the pharma-
ceutical field in Albania (11). In the same 
time, the number of the pharmacies in Alba-
nia has been increasing from year 1993 to 
year 2014 (from 1,097 pharmacies in 1994 to 
1,600 pharmacies in 2014) (7,12).  However, 
there is not a clear picture of the pharmaceu-
tical legislative development in Albania fos-
tered by the Europeanization process. The 
aim of this review is to explore how the phar-
maceutical legislation of Albania has evolved 
from 1994 to 2021 and where does it stand 
toward achieving the full approximation to 
the EU respective legislation. 
 
Methods 
This study is based on qualitative research 
techniques, especially means of content anal-
ysis. We used two sources to collect data. 
First, we consulted the Albania’s National 
Publications Office webpage and analysed all 
 
 
Roshi D, Tresa E, Lafranconi A, Burazeri G, Czabanowska K, Brand H.  Pharmaceutical policies in 
post-communist Albania: Progress and challenges toward European Union membership (Review 
article). SEEJPH 2021, posted: 19 July 2021. DOI: 10.11576/seejph-4604 
 
 
P a g e 4 | 13 
 
available legislation regarding “pharmacy”, 
“medicine” and “pharmaceutical products” 
from 1994 to 2021 (11). The second source 
of data were National Integration Plans (NIP) 
that have been published by the Government 
of Albania from 2014 to 2021 (10). In both 
cases we included in the analysis the laws and 
chapters that contained the words “Phar-
macy”, “Pharmaceuticals”, “Price”, “Medi-
cine”, “Out of Pocket”. All consulted docu-
ments are available at Appendix 1. Then, we 
used Conventional Content analysis to group 
the data and identify the “coding categories 
directly from the text data” (13). Each NIP 
has 33 chapters that cover different areas. The 
chapter which covers pharmaceutical issues 
and medicines is chapter 28 on “Consumer 
and Health Protection”. All data are pre-
sented in the results section based on four cat-
egories we identified through content analy-
sis: Sale at distance and pharmaceutical indi-
cators; Pricing policy and Pharmaceutical 
Expenditure; Clinical trials; Marketing Au-
thorization, Distribution and Storage Prac-
tices. 
 
Results and Discussion 
The law on medicines and pharmaceutical 
service has changed many times from 1994 to 
2014. The latest published version (the 2014 
one) is the most compatible to the respective 
EU directive (Directive 2001/83) (8,9). How-
ever, when comparing the EU pharmaceuti-
cal legal framework to the Albanian one, it 
results that the Albanian legal framework 
lacks many regulations such as the one on 
pharmacovigilance and the regulation on me-
dicinal products for paediatric use.  
 
Sale at distance and pharmaceutical indica-
tors 
After the fall of the communist regime (in 
1991), various reforms took place in Albania 
such as the permission of private service pro-
viders to operate, decentralization of primary 
care management, the privatization of the 
pharmaceutical and dentistry sectors, and the 
founding of the Health Insurance Institute 
(16). Data shows that the number of pharma-
cies has been increasing from 1994 to 2014 
(Table 1) (7,12). This might be related to the 
opening of pharmaceutical private universi-
ties since 2003 which resulted to a higher 
number of pharmacists graduated annually in 
Albania (17–19). Even though, the govern-
ment started to apply the professional state 
exam (to control the number and professional 
quality of pharmacist who graduated), the 
number pharmacists licenced annually con-
tinued to increase (11). The increased number 
of pharmacies is not proportional with the to-
tal population (Table 1).  
 
Table 1. Pharmaceutical indicators (7,12,20–22) 
 
INDICATOR  1990 2003 2005 
Last year 
available 
Number of pharmacies (total)  - 1097 1000 
1600 
(2014) 
Pharmacists per 100000 inhabitants 36.37 35.28 38.3 
108.4 
(2018) 
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Only the pharmacies that plan to have a con-
tract with the Compulsory Health Care Insur-
ance Fund (CHIF) must fulfil some condi-
tions before opening the pharmacy (23). As 
per the Albanian legislation, a pharmacy that 
signs a contract with the with the CHIF for 
the first time should, be at least 50 meter 
square, at least 150 meter linear away from 
an existing pharmacy and in a distance at 
least 30 meter from the health care centre 
(23).  
The Law on Medicines and Pharmaceutical 
Service of 2004 specified that: The pharma-
cies could be opened in urban areas in a dis-
tance lower than 150 meters from each other, 
depending from population density (one 
pharmacy for 3000 inhabitants), but the leg-
islations on distance is not in force anymore 
(compared to the actual law of 2014) (11). 
Pharmacies are periodically controlled/in-
spected by the National Agency for Drugs 
and Medical Devices and CHIF (The Re-
gional Branch and National Office in case the 
pharmacy has a contract with this institution), 
by the Order of Pharmacist and the Tax Ad-
ministration Office (TAO). All these institu-
tions inspect the pharmacies regarding the 
conditions on storing the medicines; the or-
der/timeline in which they keep the prescrip-
tions; if they give any non-Over The Counter 
(OTC) without prescription; if they sell med-
icines that do not have a marketing authori-
zation (contraband medicine); if they store 
the expired medicines in a non-separate area 
inside the pharmacy; if the number of the re-
imbursed medicines is the same with the one 
shown in the electronic prescription system 
(only for the pharmacies with a contract with 
CHIF); if they give a coupon after each sale; 
or/and if the employed pharmacists are li-
censed (11,14).
 A yearly report from the State Central In-
spectorate mentions that in 2017 were in-
spected and controlled 424 subjects out of 
which 352 were pharmacies and pharmaceu-
tical agencies and 48 were pharmaceutical 
distributors or importing warehouses. In this 
regard, 25 administrative measures were 
taken (24). 
In 2018, the same report showed that out of 
603 controlled subjects, 592 were pharmacies 
and pharmaceutical agencies, 11 were phar-
maceutical distributors or importing ware-
houses, 14 inspections for expired medicines 
upon request of the subjects themselves and 
one inspection in collaboration with the State 
Policy (Sector against economic and finan-
cial crime). Overall, 182 administrative 
measures were taken (25).  
The European Directive (2001/83) specifies 
the sale at distance to the public (15). In this 
regard, taking in consideration the existing 
Albanian Law on Medicines and Pharmaceu-
tical Service 105/2014, the selling of medi-
cines at distance to the public is difficult to be 
monitored (14). 
 
Pricing policy and pharmaceutical expendi-
ture 
Medicine pricing in Albania is done by an of-
ficial committee assigned by the Minister of 
Health (19). This committee aims at achiev-
ing a lower price of the medicines regardless 
the quality. The Committee uses a specific 
formula and the reference price to calculated 
the medicine price (20).  
The pricing policy since 2014 is as follows: 
i) The medicine reference price for Al-
bania should be the lowest among:  
- The wholesale prices in the ref-
erence countries. 
- The retail price the medicine has 
in its origin place. 
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- The price that the medicine has 
had in the last 12 months of im-
port (11). 
ii) The generic medicine price should 
be 80% of the patent medicine price 
registered in the National Agency for 
Drugs and Medical Devices. In case 
the patent medicine does not have a 
marketing authorization in Albania, 
then its price in the origin place 
should be taken into consideration 
(19). 
iii) The retail selling price of the medi-
cine should be the same with the 
price of the medicine in the origin 
place (19).  
In the meantime, the price margin has 
changed – Table 2 shows the price margins 
during the period 2005-2006.  
 
Table 2. Regressive margin system for medicines in Albania 
[Source: Imasheva & Seiter, 2008 (7)] 
 
TYPE OF MEDICINES  Importer and wholesale margin Retail margin 
Most Expensive  8% 15% 
Moderately expensive  10% 20% 
Non-expensive  15% 30% 
Least Expensive  18% 33% 
 
The purpose of such regressive price margin 
is to reduce the incentive for pharmacists to 
recommend expensive, branded medicines 
over cheaper generics (7). Until 2015, the 
price margin system has changed by decreas-
ing the wholesale and retail margin (11). The 
decision No.143 date 18.02.2015 stated that 
the margin of the wholesale margin should be 
11% (divided 8% for the importer and 3% for 
the distributor) and 25% for the retail seller 
(25% of the price that the medicine has once 
distributed to the pharmacy) (11). Since 
2015, in WB a lot of attention has been de-
voted to pharmaceuticals, which have be-
come one of the largest and fastest growing 
components of health expenditure (26). The 
National Health Strategy NHS aims at in-
creasing of the medicine quality, safety and 
affordability in accordance with the Euro-
pean Standards (27). This is planned to be 
achieved by: 
Reducing the prices and improving access 
through a progressive expansion of the reim-
bursable medicine list. 
- Registration of medical devices. 
- Establishing a tracking system to 
maintain, strengthen and ensure qual-
ity during all phases: production, im-
port, distribution and sale at the final 
point. 
- Achieving quality on pharmaceutical 
service available throughout the 
country. 
- Strengthening the National Agency 
for Drugs and Medical Devices (27). 
 
Table 3 indicates that the pharmaceutical ex-
penditure as part of the total health expendi-
ture has been increasing. It indicates a con-
siderable out of pocket expense on medicines 
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Table 3. Pharmaceutical expenditure in Albania (28) 
 
Pharmaceutical expenditure as a 
proportion of total health expendi-
ture 
1993 
(earliest year available) 
2007 
(last year available) 
23% 28% 
In Albania, annual expenditures on reim-
bursed medicines increased from ALL 3.5 
billion in 2007 to ALL 8.4 billion in 2013, 
due to a variety of reasons such as: expansion 
of the health insurance scheme, reimburse-
ment of innovative medicines, the tendency 
of the physicians to prescribe expensive ther-
apies, lack of rules and regulations control-
ling this sector, and lack of significant policy 
for using generic medicines as substitutes for 
expensive products with the same active sub-
stances (26). A study conducted on the af-
fordability of healthcare payments in Albania 
showed that the average nominal annual 
amount spent out of pocket per person in-
creased with 37%, from 2009 to 2015 with an 
annual average growth rate over 5% (29). 
Some of the main issues that come out of the 
NIP, are: 
- The health sector remains a major 
challenge; new initiatives aim signif-
icant changes in health care financing 
systems and achieving universal cov-
erage of ongoing initiatives. New pro-
grams for periodic population exami-
nations will improve disease preven-
tion. Introduction of universal cover-
age system is expected to improve the 
health care system and the provision 
of health services. (Appendix1) 
- The National Medicine Control Strat-
egy 2018–2022 is envisaged for ap-
proval in the last quarter of 2018. 
(The NIPs of 2018-2020). 
- The National Health Strategy 2016-
2020 was approved in May 2017 and 
aims to achieve universal healthcare 
coverage. (The NIPs of 2019-2021). 
- In terms of public health, significant 
progress needs to be made to imple-
ment the policy framework and en-
sure health care coverage for all in Al-
bania. Regarding medical devices, 
Law 89/2014 "On medical devices" 
has been revised pursuant to the Eu-
ropean regulation on medical devices. 
The revision of the law was made fol-
lowing the process of approximation 
of Albanian legislation with the Euro-
pean one and aims to increase safety 
during the use of medical devices af-
ter their placement on the market and 
increase access for patients. (The 
NIPs of 2021-2023) (11). 
The National Health Strategy (NHS) cites 
that the medicine market in Albania is well-
regulated, while medicines and pharmaceuti-
cal services are offered by the private sector 
(27). The legislation, is progressively im-
proved in line with the EU directives (27). 
The National Agency for Drugs and Medical 
Devices has been established in 2014, before 
it was known as the National Centre of Drug 
Control (27). In order to increase the access 
to safe medicines and reduce their financial 
burden, in 2015 a series of medicines were 
traded at prices around 30% cheaper com-
pared to 2013. Also, the list of essential med-
icines has been updated with 200 new medi-
cines compared to 2013, while the list of re-
imbursable medicines was updated with 
about 80 new medicines (27). In the last two 
years, cytostatic medicines are doubled, 
while medical materials for cardiology have 
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Clinical trials 
Clinical Trials have been a specific chapter of 
the Albanian Law on medicines since 1994 
and later 2004 (11). In March 2018 for the 
first time the order on approving the guide-
lines for clinical trials was published (30). 
This regulation is nearly harmonized with the 
EU Directive 2001/20 on the approximation 
of the laws, regulations and administrative 
provisions of the Member States in relation to 
the implementation of good clinical practice 
during the conduct of clinical trials on medic-
inal products for human use (30). The Euro-
pean Commission Directive 2005/28/EC of 8 
April 2005 on laying down principles and de-
tailed guidelines for good clinical practice 
(including investigational medicinal products 
for human use, the requirements for authori-
zation of the manufacturing or importation of 
such products) is far more detailed than the 
before mentioned Albanian ordinance on 
guidelines on conducting clinical trials (31). 
Therefore, this part of the pharmaceutical 
legislation lacks detailed regulation on con-
ducting clinical trials. 
 
Marketing authorization, distribution and 
storage practices 
Regarding the granting of marketing authori-
zation for medicines for human use, the pro-
cedure is nearly the same as in the EU (11). 
There is also a specific regulation on granting 
the marketing authorization for medicines for 
human use in Albania, Decision No.299 
dated 08.04.2015 on the Approval of the Reg-
ulation on Granting the Medicines Marketing 
Authorization (11). Until 2018, no specific 
regulation existed in Albania on distribution 
and storage practice, although this chapter 
was part of the law on medicines on pharma-
ceutical service 105/2014 (14,32). This law 
states that a regulation regarding the good 
distribution and storage practices should be 
approved by the minister of health and should 
be obligatory for the importers, exporters, 
pharmaceutical distributors, pharmacies and 
pharmaceutical agencies (14). In the law 
105/2014, existed an administrative offense 
for each pharmacy that did not comply with 
the foreseen practices, even though such reg-
ulation was not in place yet (14). Such issues 
were solved out in 2018, when the regulation 
on distribution and storage practice was im-
plemented for the first time (32). This ordi-
nance was based on the European Medicines 
Agency’s scientific guidelines on the quality 
of human medicines; Regulation (EC) No 
726/2004 of the European Parliament; World 
Health Organization Technical Report Series, 
No. 908, 2003, Guide to good storage prac-
tices for pharmaceuticals; US Pharmacopoeia 
1079, Good Storage and Distribution Prac-
tices; Guidelines of 5 Nov EC ember 2013 on 
Good Distribution Practice of medicinal 
products for human use (2013/C 343/01); 
Guidelines for the Storage of Essential Med-
icines and Other Health Commodities 2003; 
and Pharmaceutical Inspection Co-operation 
Scheme (PIC/S) Guide to Good Distribution 
Practice for Medicinal Products (32).  
 
Conclusion  
In conclusion, the main pillars of the pharma-
ceutical sector in Albania are well-covered 
legally but not fully in concordance with the 
EU framework. There is a need to reinforce 
the laws that regulate the opening of pharma-
cies; a detailed regulation on supervising and 
controlling the online sale of medicines and 
taking administrative measures where appro-
priate; a regulation on implementing the track 
and trace system of medicines. There is no 
regulation regarding pharmacovigilance in 
Albania. Also, unlike the EU, in Albania, 
there is no regulation on medicinal products 
for paediatric use.  
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